Herpes Simplex Type 2

HSV-2 Vaccine Induces Humoral/Cellular Responses

Published in Vaccine Weekly, July 3rd, 1995

An experimental herpes simplex type 2 (HSV-2) vaccine has been found to induce both humoral and cellular responses to the virus that are equal to or greater than those of persons with naturally acquired infection.

Genital herpes simplex virus is the major cause of genital ulcerations in Europe and North America and seroprevalence studies have shown that between 10 percent and 20 percent of Europeans and North Americans between the ages of 20 and 45 have evidence of HSV-2 infection.

"Vaccines for preventing or treating genital herpes would be a major public health advance," researcher Andria Langenberg and colleagues wrote ("A Recombinant Glycoprotein...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1995-07-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry